BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 18995891)

  • 1. Synergistic cytotoxicity of interferonalpha-2b and interleukin-2 in combination with PBMC against ovarian cancer: development of an experimental model for cellular therapy.
    Ingersoll SB; Patel S; Caballero L; Ahmad S; Edwards D; Holloway RW; Edwards JR
    Gynecol Oncol; 2009 Jan; 112(1):192-8. PubMed ID: 18995891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of a fluorescent highly tumorigenic ovarian cancer line to test cellular therapy in experimental models.
    Ingersoll SB; Ahmad S; Stoltzfus GP; Patel S; Radi MJ; Finkler NJ; Edwards JR; Holloway RW
    Int J Gynecol Cancer; 2011 Apr; 21(3):457-65. PubMed ID: 21430454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular therapy in combination with cytokines improves survival in a xenograft mouse model of ovarian cancer.
    Ingersoll SB; Ahmad S; McGann HC; Banks RK; Stavitzski NM; Srivastava M; Ali G; Finkler NJ; Edwards JR; Holloway RW
    Mol Cell Biochem; 2015 Sep; 407(1-2):281-7. PubMed ID: 26048718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Specific immune cell therapy against ovarian cancer in vivo and in vitro].
    Chang XH; Cheng HY; Cheng YX; Ye X; Guo HF; Fu TY; Zhang L; Zhang G; Cui H
    Ai Zheng; 2008 Dec; 27(12):1244-50. PubMed ID: 19079987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the cytotoxic response against ovarian cancer by immune effector cells isolated and expanded from normal donors and ovarian cancer patients.
    Ingersoll SB; Stoltzfus GP; Merchant MH; Ahmad S; Edwards CR; Ahmed A; Oyer JL; Finkler NJ; Holloway RW; Edwards JR
    Cytotherapy; 2012 Jul; 14(6):716-23. PubMed ID: 22409787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor efficacy induced by human ovarian cancer cells secreting IL-21 alone or combination with GM-CSF cytokines in nude mice model.
    Dou J; Wang Y; Wang J; Zhao F; Li Y; Cao M; Hu W; Hu K; He XF; Chu L; Jiang C; Gu N
    Immunobiology; 2009; 214(6):483-92. PubMed ID: 19389515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells.
    Pandey V; Oyer JL; Igarashi RY; Gitto SB; Copik AJ; Altomare DA
    Oncotarget; 2016 Feb; 7(6):7318-28. PubMed ID: 26802025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine-induced Killer T Cells Enhance the Cytotoxicity Against Carboplatin-resistant Ovarian Cancer Cells.
    Pan Y; Chiu YH; Chiu SC; Cho DY; Lee LM; Wen YC; Whang-Peng J; Hsiao CH; Shih PH
    Anticancer Res; 2020 Jul; 40(7):3865-3872. PubMed ID: 32620626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
    Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
    Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct and indirect antitumor effects by human peripheral blood lymphocytes expressing both chimeric immune receptor and interleukin-2 in ovarian cancer xenograft model.
    Lee JM; Yoon SH; Kim HS; Kim SY; Sohn HJ; Oh ST; Oh IH; Kim TG
    Cancer Gene Ther; 2010 Oct; 17(10):742-50. PubMed ID: 20559334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo cytokine activation of peripheral blood stem cells: a potential role for adoptive cellular immunotherapy.
    Meehan KR; Wu A; Hassan R; Miao Y; Chawla J; Slack R; Gehan E; Herscowitz HB
    J Hematother Stem Cell Res; 2001 Apr; 10(2):283-90. PubMed ID: 11359675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient inhibition of ovarian cancer by recombinant CXC chemokine ligand 10 delivered by novel biodegradable cationic heparin-polyethyleneimine nanogels.
    Yang F; Gou M; Deng H; Yi T; Zhong Q; Wei Y; Zhao X
    Oncol Rep; 2012 Aug; 28(2):668-76. PubMed ID: 22684947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of interleukin-7 gene transfection into ovarian carcinoma cell line SKOV3 in vitro and in vivo.
    Xie X; Ye DF; Chen HZ; Lu WG; Fu YF; Cheng B; Zhu H
    Gynecol Oncol; 2004 Feb; 92(2):578-85. PubMed ID: 14766250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model.
    Yoon SH; Lee JM; Cho HI; Kim EK; Kim HS; Park MY; Kim TG
    Cancer Gene Ther; 2009 Jun; 16(6):489-97. PubMed ID: 19096447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice.
    Lin X; Chen X; Wei Y; Zhao J; Fan L; Wen Y; Wu H; Zhao X
    Gynecol Oncol; 2007 Mar; 104(3):540-6. PubMed ID: 17112567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of cytokines during interaction of peripheral blood mononuclear cells with autologous ovarian cancer cells or benign ovarian tumour cells.
    Nowak M; Klink M; Glowacka E; Sulowska Z; Kulig A; Szpakowski M; Szyllo K; Tchorzewski H
    Scand J Immunol; 2010 Feb; 71(2):91-8. PubMed ID: 20384860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism.
    Yang T; Wall EM; Milne K; Theiss P; Watson P; Nelson BH
    Clin Cancer Res; 2007 Dec; 13(23):7172-80. PubMed ID: 18056198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of interleukin-12 transfection on proliferation of ovarian cancer SKOV3 cells in vitro and in vivo].
    Wang J; Zhang CQ; Liu J; Sui LH
    Ai Zheng; 2007 Dec; 26(12):1292-8. PubMed ID: 18076789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.